Homologous Recombination Deficiency clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (dose escalation) is to confirm the appropriate treatment dose. The purpose of Phase II (dose expansion) is to characterize the safety and efficacy of AMXI-5001.